Skip to main content Help with accessibility Skip to main navigation



treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases

Amber level 0


Nice TA:

Commissioning responsibility:


PbR excluded:


BNF chapter:
Immune system and Malignant Disease


Degarelix should be recommended/initiated by specialist services– AMBER0 recommendation.

Degarelix is recommended as an alternative to lutenising hormone releasing hormone agonists (LHRH) for treatment of adult male patients with advanced hormone-dependent prostate cancer without spinal metastases ONLY in the following circumstances:

  • where LHRH analogues or concomitant anti-androgens are contra-indicated.
  • in patients on androgen deprivation therapy who have a significant cardiac history/severe cardiac disease.
  • very significant, symptomatic metastatic disease, and locally advanced disease to shrink the metastases.
  • impending bladder outlet obstruction due to prostate cancer.


LSCMMG Recommendation:

Amber level 0

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
What do the colours mean?

Last Updated: 28 - Feb - 2023